Petrelintide and the Amylin Moment: Zealand and Roche's Phase 2 Win on Tolerability Heads to ADA 2026 — June 1, 2026 Peptide Research Update
Table of Contents
Amylin Steps into the Spotlight: Petrelintide's Phase 2 Win
For the past several years the obesity story has been dominated by incretins — GLP-1 agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide. In 2026 a second mechanism is moving from supporting cast to headliner: amylin. Petrelintide (formerly ZP8396), a once-weekly long-acting amylin receptor agonist from Zealand Pharma developed in partnership with Roche and its U.S. subsidiary Genentech, reported positive Phase 2 ZUPREME-1 results on March 5, 2026. With full data and a fresh presentation slated for the American Diabetes Association (ADA) 2026 Scientific Sessions (June 5-8, New Orleans), petrelintide has become one of the most closely watched non-incretin peptides in weight management.
What ZUPREME-1 Showed
ZUPREME-1 was a Phase 2 dose-finding trial in 493 people living with overweight and obesity, with a mean baseline body-mass index of roughly 37 kg/m2. Participants received once-weekly subcutaneous petrelintide (escalated every fourth week) or placebo. The headline efficacy result: up to 10.7% mean weight loss from baseline at week 42 using the efficacy estimand, compared with 1.7% for placebo. Importantly, all five active treatment arms produced statistically significant and clinically meaningful weight loss versus placebo as early as 28 weeks, and weight loss was sustained through week 42 — a sign that the effect was durable across the dose range rather than confined to a single high dose.
The Real Story Is Tolerability
What set the readout apart was not the magnitude of weight loss — which is solid but below the peak numbers posted by high-dose incretin and triple-agonist drugs — but the tolerability profile. Rates of gastrointestinal adverse events were comparable to placebo, and the proportion of participants who experienced vomiting was actually lower on petrelintide than on placebo. Nausea, vomiting, and other GI effects are the most common reasons people discontinue GLP-1-based therapies, so an agent that delivers double-digit weight loss without that burden could meaningfully change who can start, tolerate, and stay on treatment. Analysts framed the data as setting a new bar for amylin tolerability.
Why Amylin Matters as a Mechanism
Amylin is a hormone co-secreted with insulin by the pancreas. It curbs appetite, slows gastric emptying, and promotes satiety through pathways that overlap with but are distinct from GLP-1 signaling. That distinct mechanism is the strategic point: amylin agonists may achieve appetite control with a different — and apparently gentler — side-effect signature, and they can be layered on top of incretins for additive effect. The most advanced example of that combination thinking is cagrilintide (an amylin analog) paired with semaglutide as CagriSema, and Novo Nordisk's amycretin combines amylin and GLP-1 activity in a single molecule. Petrelintide's differentiation is its emphasis on a clean standalone profile that could also serve as a combination backbone.
The Roche Partnership and the Road to Phase 3
Petrelintide is not a small-company long shot. In 2025 Zealand Pharma and Roche entered an exclusive global collaboration to co-develop and co-commercialize the drug, with Genentech leading in the United States. That partnership puts major commercial muscle and conviction behind amylin biology. Zealand and Roche plan to present full ZUPREME-1 data, including a nine-week safety follow-up period, at a 2026 scientific conference, and to initiate Phase 3 later in 2026. Petrelintide is being positioned as a potential foundational obesity therapy — both on its own and as a backbone for combinations with incretin drugs.
ADA 2026: An Imminent Catalyst Cluster
The ADA 2026 Scientific Sessions (June 5-8, New Orleans) are the next major proving ground. Zealand confirmed on May 27, 2026 that it will present petrelintide data, with the ZUPREME-1 readout selected for the ADA Official Press Program; late-breaking posters are embargoed until Friday, June 5. Petrelintide will share the stage with a dense cluster of obesity readouts — including MetaVia's dual oxyntomodulin analog DA-1726 and GPR119 agonist vanoglipel, plus expected detail on retatrutide and survodutide — making this one of the most catalyst-rich obesity meetings in recent memory.
What It Means for Readers
Petrelintide is investigational and not approved or available outside clinical trials, and full peer-reviewed data are still pending. But the trajectory is clear: amylin is maturing into a genuine third pillar of obesity pharmacology alongside GLP-1 and combination incretins, and the competitive battleground is shifting from peak weight loss toward quality, durability, and tolerability of weight loss. For anyone tracking where weight management is headed, petrelintide and the broader amylin class are now essential to watch — and the ADA 2026 sessions in early June should sharpen the picture considerably. As always, this is educational information about peptide research, not medical advice; treatment decisions should be made with a qualified healthcare professional.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.